Closed · PA-07-056 · CFDA 93.847 · Discretionary
Pancreatic Development and Regeneration: Toward Cellular Therapies for Diabetes (R01)
Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.
- Varies
- Award range
- Closed
- Status
- -
- Close date
- -
- Expected awards
The verdict
Pancreatic Development and Regeneration: Toward Cellular Therapies for Diabetes (R01) is a closed discretionary listing from National Institutes of Health that offered Varies by applicant. Future funding cycles may be published under the same CFDA number.
- Varies
- award range
- Closed
- application status
- 93.847
- CFDA program
Opportunity snapshot. This Grants.gov announcement - Pancreatic Development and Regeneration: Toward Cellular Therapies for Diabetes (R01) - is cataloged under number PA-07-056 and tied to CFDA assistance listing 93.847, posted by National Institutes of Health. Grants.gov currently shows the opportunity as closed, first posted on November 21, 2006 and last updated on December 5, 2008. The funding category is Discretionary, delivered as a grant.
Award economics. The award range on file is Varies by applicant. Cost sharing is not required, so applicants do not need to commit matching funds to be competitive on this opportunity. Federal award ranges are often upper bounds; actual allocations reflect program appropriations, the strength of the applicant pool, and the evaluation committee's scoring.
Deadline and action path. This opportunity is closed. Monitoring the parent program page is the most reliable way to catch re-announcements in the next funding cycle. Every Grants.gov submission requires an active SAM.gov registration and a Unique Entity ID. Review the Eligibility section below carefully, federal eligibility categories (nonprofit, state or local government, tribal, individual, educational institution, small business) have distinct registration and reporting requirements. Pre-application outreach to the listed agency contact is permitted and often welcomed, it helps clarify scope and scoring priorities. Before acting on the deadline or award figures above, verify them directly on the official Grants.gov listing, amendments can change dates and amounts after this page was last refreshed.
Award Range
Varies by applicant
Close Date
Not specified
Multiple Receipt Dates - See Link to Full Announcement for details.
Posted
November 21, 2006
Instrument
Grant
Description
-Purpose. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH), invites applications to understand how endogenous pancreatic beta cells are made by studying pancreatic development, with the goal of making pancreatic islets in culture, to explore the potential of animal or human stem/progenitor cells (embryonic or adult; if human embryonic, only NIH-approved human embryonic stem cell lines may be used) as a source for making pancreatic islets, and to determine the basic mechanisms underlying beta cell regeneration in the adult as a basis for producing new cellular therapies for diabetes. This Funding Opportunity Announcement (FOA) is intended to stimulate the application of advances made in developmental biology, stem cell biology, and diabetes to develop new strategies for diabetes therapy, either through cell replacement or regeneration. This FOA is intended to intensify investigator-initiated research, to attract new investigators to the field, and to encourage interdisciplinary approaches to research in this area. -Mechanism of Support. This FOA will utilize the NIH Research Project Grant (R01) award mechanism. -Funds Available and Anticipated Number of Awards. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism numbers, quality, duration, and costs of the applications received.
Eligibility
Grants.gov lists this opportunity under eligibility category codes 00, 01, 02, 04, 05, 06, 07, 08, 11, 12, 13, 20, 22, 23, 25. These codes correspond to applicant types (state/local government, tribal organization, nonprofit, educational institution, individual, small business, etc.) defined in Grants.gov's own eligibility reference. See the current Grants.gov eligibility categories or check the official listing below for this opportunity's exact eligibility statement.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Parent Grant Program
Diabetes, Endocrine, and Metabolic Disease Research
National Institutes of Health
Agency Contact
NIH OER Webmaster FBOWebmaster@OD.NIH.GOV
Key Dates
Frequently Asked Questions
What is this grant opportunity?
Is this opportunity still open?
How much funding is available?
How do I apply?
More from National Institutes of Health
Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)
Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)
Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required)
Development of Collaborative Research Facilities or Research-Resource Facilities (C06 Clinical Trial Not Allowed)
Research Grants in Clinical Informatics (R01 Clinical Trial Optional)
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
Related
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |